Featured Poster: Dupilumab Improves Urticaria Signs and Symptoms and Quality of Life in Patients with Chronic Spontaneous Urticaria
In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Maurer and colleagues present data from a phase 3 trial of dupilumab use for chronic spontaneous urticaria
By Dermsquared Editorial Team | June 16, 2023
Chronic spontaneous urticaria (CSU) is a chronic inflammatory disease characterized by wheals, angioedema, or both that recur for more than 6 weeks and cause itching and burning. The current standard of care is antihistamines, but many patients continue to experience disease burden despite this treatment.
This poster presents data from LIBERTY-CSU CUPID Study A, a randomized, placebo-controlled, phase 3 trial of dupilumab for up to 24 weeks in patients at least 6 years of age with CSU who remain symptomatic despite treatment with antihistamines.
The study found that dupilumab led to an average reduction in mean Urticaria Activity Score over 7 days (UAS7) of 20.5 points compared to a reduction of 12.0 points by placebo. Additionally, dupilumab had a mean reduction of 29.6 points in the Chronic Urticaria Quality of Life questionnaire (CU-Q2ol) compared to a reduction of 21.0 points by placebo.